NEW YORK, Sept. 29 (GenomeWeb News) - Agencourt Bioscience said today that it has struck a deal under which it will become the preferred provider of gene sequencing services to customers of Invitrogen's SAGE (Serial Analysis of Gene Expression) technology.
Under the deal, Invitrogen's I-SAGE kits will include discounted sequencing services from Agencourt.
Additional terms of the arrangement were not provided.
"The cost of sequencing has limited the widespread adoption of SAGE," said Kevin McKernan, vice president co-CSO of Agencourt, said in a statement. "With Agencourt making sequencing more accessible and affordable to more researchers, SAGE may become a more commonly used alternative to microarrays."